Arbekacin clinical trials
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How each study uses arbekacin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2013 (3)
| Year | Studies |
|---|---|
| 2013 | 3 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses arbekacin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial PneumoniaCompletedPhase 1Meiji Seika Pharma Co., Ltd.NCT02459158Written as ME1100 inhalation solutionHow we know
- Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular DystrophyStatus unknownPhase 2Kobe UniversityNCT01918384Written as NPC-14How we know
- Pharmacokinetics and Safety Study of ME1100 in Healthy VolunteersCompletedPhase 1Meiji Seika Pharma Co., Ltd.NCT01907776Written as ME1100 inhalation solutionHow we know
- Intrapulmonary Pharmacokinetics of ME1100 in Healthy VolunteersCompletedPhase 1Meiji Seika Pharma Co., Ltd.NCT01961830Written as ME1100 inhalation solutionHow we know
Codes
What other systems call arbekacin · ClinicalTrials.gg INT002969
- MeSH (NLM) C031986arbekacinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) G7V6SLI20LARBEKACINConfirmed FDA, NLM, Wikidata
- RxNorm 26397Confirmed FDA, Wikidata
- Wikidata Q4784668arbekacinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C76145ArbekacinConfirmed FDA, Wikidata
- DrugBank DB06696One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C031986 | arbekacin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | G7V6SLI20L | ARBEKACIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 26397 | — | Confirmed FDA, Wikidata |
| Wikidata | Q4784668 | arbekacin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C76145 | Arbekacin | Confirmed FDA, Wikidata |
| DrugBank | DB06696 | — | One source Wikidata |
Also registered as arbekacin sulfate (UNII G7395HZ992 · RxNorm 237044).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.